Volume 24, Issue 5 pp. 685-690

Antibody-mediated rejection of renal allograft in combined liver–kidney transplant

Rolf N. Barth

Rolf N. Barth

Division of Transplantation, Department of Surgery

Search for more papers by this author
Luis Campos

Luis Campos

Division of Transplantation, Department of Surgery

Search for more papers by this author
Debra L. Kukuruga

Debra L. Kukuruga

Immunogenetics Laboratory

Search for more papers by this author
Cinthia Drachenberg

Cinthia Drachenberg

Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA

Search for more papers by this author
Benjamin Philosophe

Benjamin Philosophe

Division of Transplantation, Department of Surgery

Search for more papers by this author
First published: 18 November 2009
Citations: 10
Corresponding author: Rolf N. Barth, MD, Division of Transplantation, University of Maryland School of Medicine, 29 S. Greene Street, Suite 200, Baltimore, MD 21201, USA.
Tel.: 410 328 5408; fax: 410 328 6343;
e-mail: [email protected]

No financial support was provided to conduct this work.

Abstract

Barth RN, Campos L, Kukuruga DL, Drachenberg C, Philosophe B. Antibody-mediated rejection of renal allograft in combined liver–kidney transplant.
Clin Transplant 2009 DOI: 10.1111/j.1399-0012.2009.01161.x
© 2009 John Wiley & Sons A/S.

Abstract: Liver transplantation is performed based on ABO blood type compatibility without dependence on crossmatch results. Combined liver–kidney transplantation (CLKT) is similarly performed without dependence of crossmatch results as the liver is thought to confer protection to the renal allograft against alloantibody. We report a case of CLKT in a sensitized patient with antibody-mediated rejection (AMR) of the renal allograft. AMR was confirmed with C4d staining and serial monitoring of donor-specific antibody (DSA). Despite intensive therapy directed against AMR and the presence of the liver allograft, the patient demonstrated increasing titers of alloantibody, never demonstrated adequate renal function, and ultimately expired after two months. This result demonstrates the potential for AMR of the renal allograft in sensitized recipients of CLKT.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.